A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
Clinical trial NCT03682536 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03682536
- Sponsor
- Celgene
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-02
- Primary completion
- 2023-03-31
- Enrollment
- 363
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.